Health Care Technology
Micro Medical Solutions Expands Board Of Directors With Appointment Of Vince Burgess And John Dahldorf
Share
WOBURN, Mass., Nov. 14, 2025 /PRNewswire/ -- Micro Medical Solutions (MMS), an innovative medical device company focused on improving outcomes for patients suffering from Critical Limb Threatening Ischemia (CLTI), today announced the appointment of Vince Burgess and John Dahldorf to its Board of Directors. They join George Quinoy, Chairman of the Board and President & Chief Executive Officer, and Dr. Ron Solar, Board Member, as MMS strengthens its leadership team in preparation for commercialization of its MicroStent™ technology.
"We are pleased to welcome Vince and John to the MMS Board," said George Quinoy, Chairman, President & CEO of Micro Medical Solutions. "Their combined expertise in scaling medical device companies, managing public-company operations, and guiding financial and commercial execution will be invaluable as we advance through FDA review and prepare for market launch."
Joining the MMS Board in November 2025, Vince Burgess most recently served as President, CEO, and Director of Acutus Medical, Inc. from 2017–2022. He previously was a Venture Partner with OrbiMed Advisors, a global healthcare investment firm, and a founding executive at Volcano Corporation, where he served as President of Advanced Imaging Systems and led marketing and business development from 2002 to 2010. Mr. Burgess currently serves on the Board of Directors of Tela Bio, Inc. and has held prior board roles with Bolt Medical, NeuroPace, Sonendo, Keystone Heart, Vessix Vascular, Cryterion Medical, and CardiAQ. He earned a B.S. in Business Administration from the University of Southern California and an M.B.A. from the University of California, Los Angeles.
John Dahldorf brings more than 25 years of experience leading finance and accounting functions for both public and private healthcare companies. He currently serves as Chief Financial Officer of Q'Apel Medical, Inc., a neurovascular device company, and as a Board Member of Hyperfine, Inc. Mr. Dahldorf previously served as Chief Financial Officer for Volcano Corporation where he was instrumental in the acquisition by Royal Philips. He also served as CFO at Digirad Corporation, Acutus Medical, SCN Bestco, and Adagio Medical Holdings. He holds a B.S. in Finance and an M.B.A. from Western Illinois University.
"Vince and John each bring proven leadership in innovation, commercialization, and financial strategy," said Dr. Ron Solar, Board Member. "Their experience will strengthen MMS's ability to execute effectively as we move toward approval and market readiness."
The MicroStent™, which has received FDA Breakthrough Device Designation, is designed to improve blood flow, promote wound healing, and reduce amputations in patients with CLTI. The device is currently under Premarket Approval (PMA) review.
About MMS
Micro Medical Solutions (MMS) is an innovative medical device company addressing the critical unmet need in BTK arterial disease. Our technology is designed to treat patients at high risk of amputation-driven by global health trends including diabetes, hypertension, and aging populations. We are positioned at the intersection of significant clinical demand, regulatory momentum, and market opportunity.
For more information: www.micromedicalsolutions.net.
View original content to download multimedia:https://www.prnewswire.com/news-releases/micro-medical-solutions-expands-board-of-directors-with-appointment-of-vince-burgess-and-john-dahldorf-302616089.html
SOURCE Micro Medical Solutions
Frequently Asked Questions
What is Micro Medical Solutions (MMS)?
MMS is a medical device company focused on improving outcomes for patients with Critical Limb Threatening Ischemia (CLTI).
What is MicroStent™?
MicroStent™ is MMS's technology, designed to improve blood flow, promote wound healing, and reduce amputations in CLTI patients. It has FDA Breakthrough Device Designation.
Who are Vince Burgess and John Dahldorf?
They are newly appointed members of the MMS Board of Directors, bringing expertise in scaling medical device companies, finance, and commercial execution.
First published on Fri, Nov 14, 2025
Enjoyed what you read? Great news – there’s a lot more to explore!
Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!
Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.
Head to the TechDogs homepage to Know Your World of technology today!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
Protecting Print Fleets: Symphion Addresses Complacency In Printer Endpoint Protection With Two New Offerings
School Specialty LLC Announces Acquisition Of Nasco Education U.S.
Scowtt Raises $12M Series A To Transform Performance Marketing With AI-Powered Advertising Platform
Unified.To Powers 550% API Usage Growth In Six Months Amid Rising AI Adoption
Broadridge's Distributed Ledger Repo Platform Processes $368 Billion In Average Daily Trade Volumes In November
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion